SCHEMBL1681065

SCHEMBL1681065

N#Cc1ccc(Oc2ccccc2)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 3/20 0.50
LTA4H P09960 6/20 0.46
TSHR P16473 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
PIN1 Q13526 1/20 0.45
ERBB2 P04626 1/20 0.45
GLA P06280 1/20 0.45
POLB P06746 1/20 0.45
HPGD P15428 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
RAF1 P04049 1/20 0.44
MAP2K1 Q02750 1/20 0.44
CHEK1 O14757 1/20 0.44
CYP11B1 P15538 1/20 0.44
CYP11B2 P19099 1/20 0.44
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11473119 0.98 CYP19A1 (0.49) CYP19A1LTA4HTSHRMEN1KMT2A
SCHEMBL13895544 0.85 CYP19A1 (0.59) CYP19A1MEN1KMT2APOLBSMN1; SMN2
SCHEMBL17423720 0.84 CYP19A1 (0.68) CYP19A1LTA4HSMN1; SMN2CYP11B1CYP11B2
SCHEMBL10392865 0.83 P2RX3 (0.47) CYP19A1LTA4HMEN1KMT2AHPGD
SCHEMBL3413808 0.83 ALDH1A1 (0.52) CYP19A1TSHRMEN1KMT2APOLB
SCHEMBL12634621 0.83 SLC22A12 (0.45) CYP19A1MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL19405907 0.81 MAOB (0.54) CYP19A1MAOA
SCHEMBL24155920 0.80 SMN1; SMN2 (0.58) MEN1KMT2APIN1ERBB2GLA
SCHEMBL21045811 0.79 DGAT1 (0.44) CYP19A1LTA4H
SCHEMBL21664072 0.78 KCNA3 (0.42) GLASMN1; SMN2CHEK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020141439-A1 HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) 2020-07-09 WO disclosed
WO-2020141439-A1 HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) 2020-07-09 WO disclosed
US-20200206233-A1 HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) 2020-07-02 US disclosed
US-20200206233-A1 HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) 2020-07-02 US disclosed
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND NAKAMOTO KAZUTAKA 2011-08-11 US disclosed
US-7932272-B2 Antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-04-26 US disclosed
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-09-10 US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
EP-1782811-A1 NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-05-09 EP disclosed
EP-1669348-A1 NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND Eisai Co., Ltd. (JP) 2006-06-14 EP disclosed
EP-0091464-B1 METHOD FOR THE PREPARATION OF CYANO-HETEROCYCLES SCHERING AKTIENGESELLSCHAFT (DE) 1986-04-16 EP disclosed
EP-0091464-A1 METHOD FOR THE PREPARATION OF CYANO-HETEROCYCLES. SCHERING AG (DE) 1983-10-19 EP disclosed
WO-1983001446-A1 METHOD FOR THE PREPARATION OF CYANO-HETEROCYCLES VORBRÜGGEN, Helmut 1983-04-28 WO disclosed
US-4212980-A REVERSAL OF AMNESIA, TREATMENT OF SENILITY WARNER-LAMBERT COMPANY (US) 1980-07-15 US disclosed
US-4212980-A REVERSAL OF AMNESIA, TREATMENT OF SENILITY WARNER-LAMBERT COMPANY (US) 1980-07-15 US disclosed
US-4212980-A REVERSAL OF AMNESIA, TREATMENT OF SENILITY WARNER-LAMBERT COMPANY (US) 1980-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200206233-A1 HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS IDH1, IDH2, IDH3A CYP19A1 324/4885LTA4H 1969/4885TSHR 4227/4885
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND ERG28, CYP51A1, XPO1 CYP19A1 1812/4885LTA4H 1046/4885TSHR 3875/4885
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound XPO1, THPO, G6PD CYP19A1 3015/4885LTA4H 1912/4885TSHR 3836/4885
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound ERG28, DPM1, CYP51A1 CYP19A1 1952/4885LTA4H 1115/4885TSHR 3952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.